Market news

Investors need to pay close attention to CTKB stock based on the movements in the options market lately.

Complementary Technologies Deliver an Integrated, End-to-End Clinical Flow Cytometry Workflow for Laboratories Across Europe Cytek Biosciences and Sysmex Europe Collaborate Cytek Biosciences and Sysmex Europe have signed an agreement establishing a strategic collaboration to enhance clinical flow cytometry workflows and expand access to innovative diagnostic solutions. By combining their complementary technologies, the collaboration will provide an integrated, end-to-end clinical flow cytometry

On August 5, Cytek Biosciences (NASDAQ:CTKB) reported financial results for the second quarter ended June 30, and the report reads like two different companies at once. Revenue climbed, margins widened, and the installed base of instruments kept expanding. At the same time, the net loss more than doubled from a year earlier and adjusted EBITDA […]

FREMONT, Calif., Sept. 03, 2026 (GLOBE NEWSWIRE) -- As clinical laboratories seek deeper cellular insights, greater efficiency, and more streamlined approaches to cell analysis, spectral flow cytometry leader Cytek Biosciences, Inc. (Nasdaq: CTKB) will showcase its advanced solutions at two leading clinical cytometry events this fall: the European Society for Clinical Cell Analysis (ESCCA) 2026 Conference and ICCS 2026, the 41st Annual International Clinical Cytometry Meeting & Course. Set apart

FREMONT, Calif., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Cytek Biosciences, Inc. (Nasdaq: CTKB), a leading cell analysis solutions company, today announced the company will be participating in the following investor conferences.Wells Fargo 21st Annual Healthcare Conference in Boston, MACFO William McCombe will be participating in investor meetings on Tuesday, September 8, 2026Morgan Stanley 24th Annual Global Healthcare Conference in New York, NYCEO Wenbin Jiang and CFO William McCombe will be partic

FREMONT, Calif., Aug. 21, 2026 (GLOBE NEWSWIRE) -- Cytek Biosciences, Inc. (“Cytek Biosciences,” “Cytek,” or the “Company”) (Nasdaq: CTKB), a leading cell analysis solutions company, today announced that a jury in the United States District Court for the District of Delaware returned a verdict in the patent infringement action brought by Beckman Coulter, Inc. The jury found in Cytek’s favor on three of the four asserted patent claims, finding noninfringement and invalidity as to each of those th

Detailed price information for Cytek Biosciences Inc (CTKB-Q) from The Globe and Mail including charting and trades.

Detailed price information for Zimmer Biomet Holdings (ZBH-N) from The Globe and Mail including charting and trades.

Cytek Biosciences (CTKB) delivered earnings and revenue surprises of -150.00% and +1.66%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

FREMONT, Calif., Aug. 05, 2026 (GLOBE NEWSWIRE) -- Cytek Biosciences, Inc. (“Cytek Biosciences” or “Cytek”) (Nasdaq: CTKB), a leading cell analysis solutions company, today reported financial results for the second quarter ended June 30, 2026. Recent Highlights Total revenue for the second quarter of 2026 was $48.1 million, representing a 6% increase compared to the second quarter of 2025Launched Cytek Borealis™, a new 7-laser full spectrum flow cytometer with new and proprietary reagents enabli

Cytek Biosciences (NASDAQ:CTKB) reported second-quarter 2026 revenue growth of 6% year over year, supported by double-digit gains in the United States and China, while continued weakness in Europe and parts of Asia-Pacific limited overall growth. Revenue for the quarter ended June 30 was $48.1 mill

Cytek Biosciences (CTKB) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Champions Oncology and Cytek Biosciences have different growth drivers and valuations, but which life sciences stock offers better long-term upside? Let's dive in.

FREMONT, Calif., July 22, 2026 (GLOBE NEWSWIRE) -- Cytek Biosciences, Inc. (“Cytek Biosciences” or “Cytek”) (Nasdaq: CTKB), today announced that it will report financial results for the second quarter of 2026 after market close on Wednesday, August 5, 2026. The company’s management will webcast a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time to discuss its results, business developments and outlook. Live audio of the webcast will be available on the “

Cytek Bellevue Innovation Center Cytek® Biosciences has opened a new innovation center in Bellevue, Washington. The facility includes R&D laboratories and dedicated areas for instrument service training and customer demonstrations, along with assembly and testing operations. The Bellevue innovation center underscores Cytek’s continued investment in infrastructure that supports its long-term growth and reinforces its efforts to advance high-dimensional cell analysis through innovation, training,